Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Assets (2019 - 2025)

Keros Therapeutics filings provide 7 years of Assets readings, the most recent being $338.0 million for Q4 2025.

  • On a quarterly basis, Assets fell 45.12% to $338.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $338.0 million, a 45.12% decrease, with the full-year FY2025 number at $338.0 million, down 45.12% from a year prior.
  • Assets hit $338.0 million in Q4 2025 for Keros Therapeutics, down from $742.8 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $784.6 million in Q1 2025 to a low of $226.7 million in Q2 2022.
  • Median Assets over the past 5 years was $347.2 million (2023), compared with a mean of $410.2 million.
  • Biggest five-year swings in Assets: skyrocketed 325.35% in 2021 and later crashed 45.12% in 2025.
  • Keros Therapeutics' Assets stood at $255.3 million in 2021, then increased by 20.19% to $306.8 million in 2022, then grew by 20.62% to $370.0 million in 2023, then soared by 66.44% to $615.9 million in 2024, then crashed by 45.12% to $338.0 million in 2025.
  • The last three reported values for Assets were $338.0 million (Q4 2025), $742.8 million (Q3 2025), and $757.2 million (Q2 2025) per Business Quant data.